MXPA03005031A - Composicion vacunal que contiene factor de crecimiento transformante alfa. - Google Patents

Composicion vacunal que contiene factor de crecimiento transformante alfa.

Info

Publication number
MXPA03005031A
MXPA03005031A MXPA03005031A MXPA03005031A MXPA03005031A MX PA03005031 A MXPA03005031 A MX PA03005031A MX PA03005031 A MXPA03005031 A MX PA03005031A MX PA03005031 A MXPA03005031 A MX PA03005031A MX PA03005031 A MXPA03005031 A MX PA03005031A
Authority
MX
Mexico
Prior art keywords
tgfagr
growth factor
composition containing
vaccine composition
transforming growth
Prior art date
Application number
MXPA03005031A
Other languages
English (en)
Inventor
Nieto Gerardo Enrique Guillen
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of MXPA03005031A publication Critical patent/MXPA03005031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Abstract

La presente invencion esta relacionada con el campo de la inmunologia y la medicina humana, en particular con la inmunoterapia activa especifica de tumores malignos dependientes del TGFa, para su crecimiento, asi como para el tratamiento de otras enfermedades que dependan del TGFa, para su crecimiento, asi como para tratamiento de otras enfermedades que dependan del TGFa, mediante un preparado vacunal capaz de provocar una reaccion de inmunocastracion del TGFa autologo. Otro objeto importante de esta invencion es la obtencion de un preparado vacunal que incluya una combinacion del TGFa con otros ligados del EGF-R, tales como el factor de crecimiento epidermico (EGF), capaz de inhibir la proliferacion de tumores cuya progresion dependen de estos factores de crecimiento. De esta manera se evita la resistencia que puede generar el tumor a vacunas que contengan cada uno de estas moleculas por separado.
MXPA03005031A 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa. MXPA03005031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000286A CU23077A1 (es) 2000-12-06 2000-12-06 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
PCT/CU2001/000011 WO2002045738A2 (es) 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa

Publications (1)

Publication Number Publication Date
MXPA03005031A true MXPA03005031A (es) 2004-09-10

Family

ID=34109588

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005031A MXPA03005031A (es) 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa.

Country Status (21)

Country Link
US (1) US20030054011A1 (es)
EP (1) EP1339425B1 (es)
JP (1) JP2004521091A (es)
KR (1) KR100834383B1 (es)
CN (2) CN1482916A (es)
AR (1) AR031785A1 (es)
AT (1) ATE439855T1 (es)
AU (2) AU2152002A (es)
BR (1) BR0116017A (es)
CA (1) CA2430621A1 (es)
CU (1) CU23077A1 (es)
DE (1) DE60139633D1 (es)
EA (1) EA006240B1 (es)
ES (1) ES2332125T3 (es)
MX (1) MXPA03005031A (es)
MY (1) MY141122A (es)
NZ (1) NZ526283A (es)
PE (1) PE20020696A1 (es)
UY (1) UY27060A1 (es)
WO (1) WO2002045738A2 (es)
ZA (1) ZA200304416B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
KR101323845B1 (ko) 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CN113855792B (zh) * 2021-12-01 2022-03-01 上海惠盾因泰生物科技有限公司 重组hEGF-CRM197肿瘤治疗性疫苗配制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals

Also Published As

Publication number Publication date
EA006240B1 (ru) 2005-10-27
AU2002221520B2 (en) 2007-10-11
UY27060A1 (es) 2002-03-22
MY141122A (en) 2010-03-15
US20030054011A1 (en) 2003-03-20
AU2152002A (en) 2002-06-18
KR100834383B1 (ko) 2008-06-09
JP2004521091A (ja) 2004-07-15
EP1339425A2 (en) 2003-09-03
EP1339425B1 (en) 2009-08-19
EA200300638A1 (ru) 2003-10-30
CN101406692A (zh) 2009-04-15
CA2430621A1 (en) 2002-06-13
DE60139633D1 (de) 2009-10-01
ES2332125T3 (es) 2010-01-27
CU23077A1 (es) 2005-08-17
WO2002045738A3 (es) 2003-02-20
KR20030061424A (ko) 2003-07-18
AR031785A1 (es) 2003-10-01
WO2002045738A2 (es) 2002-06-13
NZ526283A (en) 2004-11-26
PE20020696A1 (es) 2002-09-19
CN1482916A (zh) 2004-03-17
BR0116017A (pt) 2004-01-13
ATE439855T1 (de) 2009-09-15
ZA200304416B (en) 2004-07-07

Similar Documents

Publication Publication Date Title
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
ATE330967T1 (de) An her2 bindende peptidverbindungen
HUP0201737A2 (hu) Anti-CTLA-4 antitestek alkalmazása
HUP0002760A2 (hu) CCK-B/gasztrin-receptor elleni ellenanyagok termelődését kiváltó immunogén készítmények, és alkalmazásuk tumorok kezelésére
DE60135005D1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
MX2009005293A (es) Novedosos anticuerpos antiproliferacion.
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
MXPA03005031A (es) Composicion vacunal que contiene factor de crecimiento transformante alfa.
ATE524192T1 (de) Zur immunmodulation geeignetes peptid
MX2021010862A (es) Arn terapeutico para el cancer de prostata.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
EA200700598A1 (ru) Противоопухолевая вакцина, способ получения противоопухолевой вакцины и способ проведения противоопухолевой иммунотерапии
MY162106A (en) Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor.their use in the treatment of cancer.
MD3626731T2 (ro) Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și a altor cancere
MX2021015501A (es) Anticuerpos y metodos de uso.
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.
MY195821A (en) Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей

Legal Events

Date Code Title Description
FA Abandonment or withdrawal